Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1257902

registered interest
date	02/12/2020
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	HIV Infection: Preventive Medicine
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government when they estimate the Dapivirine vaginal ring will be available to women (1) in the UK, and (2) abroad; and what plans they have to ensure that it is free at the point of delivery.
tabling member printed	Baroness Tonge
uin	HL11056
answer	answer is ministerial correction date of answer 15/12/2020 answer text <p>The Government has no specific plans to make the Dapivirine vaginal ring available to women in the United Kingdom. The <strong>Dapivirine Vaginal Ring 25mg</strong> was approved in accordance with the legal basis of Article 58 of Regulation (EC) No 726/2004. This legal basis is intended exclusively for markets outside the European community. The product is not authorised in the UK and the company have not sought a specific medical authorisation in the UK. However, the Government remains committed to reaching zero new HIV transmissions in England by 2030. Careful consideration will be given to the recommendations made in the independent HIV Commission’s recently published report on reaching the 2030 target as we develop the Sexual and Reproductive Health Strategy and HIV Action Plan, which we plan to publish in 2021.</p><p>In terms of the use of this product abroad, the decision on whether or not to use the product and its availability is a matter for national regulators. It is anticipated rollout of the Dapivirine vaginal ring to some African countries may begin by mid-2021. The cost of the ring has been kept as low as possible. The goal is for the ring to be publicly funded and provided to women at no cost.</p> answering member printed Lord Bethell question first answered 15/12/2020 17:38:13 answering member 4708 label Biography information for Lord Bethell
tabling member	200 label Biography information for Baroness Tonge

1256154

registered interest
date	26/11/2020
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Human Papillomavirus: Vaccination
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what assessment they have made of delays to HPV vaccinations arising from the COVID-19 pandemic; and when they expect to have rectified any such delays.
tabling member printed	Baroness Tonge
uin	HL10786
answer	answer is ministerial correction date of answer 13/01/2021 answer text <p>Due to the COVID-19 pandemic, all educational settings were closed from 23 March 2020, pausing the delivery of the 2019/20 school immunisation programmes.</p><p>In June 2020, NHS England and NHS Improvement commissioned school-aged immunisation providers were able to implement their restoration and recovery plans to commence partially delivered or incomplete programmes during the summer period. This included the delivery of programmes in school and community settings following a robust risk assessment in line with United Kingdom COVID-19 guidance. As such, by the end of July 2020, 91% of all NHS England and NHS Improvement commissioned providers were delivering school aged immunisation programmes, ensuring those eligible for the human papillomavirus vaccine had been offered at least one dose of the vaccine. The school-aged immunisation providers have continued to operationalise their restoration and recovery plans, with delivery that continued throughout August and September 2020 in line with the Government’s guidelines.</p> answering member printed Lord Bethell question first answered 13/01/2021 12:55:54 answering member 4708 label Biography information for Lord Bethell
tabling member	200 label Biography information for Baroness Tonge

1256174

registered interest
date	26/11/2020
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Vaccination
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government when they plan to publish the national vaccine strategy as announced in their consultation Advancing our health: prevention in the 2020s, published on 22 July 2019.
tabling member printed	Baroness Tonge
uin	HL10787
answer	answer is ministerial correction date of answer 11/12/2020 answer text <p>The publication of England’s national vaccine strategy has been delayed as a result of our ongoing focus on responding to the unprecedented COVID-19 pandemic. As such, plans for the vaccine strategy will be kept under review. We endeavour to update and refresh the strategy in 2021, to accurately reflect the changing landscape and investment in vaccine development carried out by the COVID-19 Vaccine Taskforce.</p> answering member printed Lord Bethell question first answered 11/12/2020 14:45:01 answering member 4708 label Biography information for Lord Bethell
tabling member	200 label Biography information for Baroness Tonge

1252025

registered interest
date	16/11/2020
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Contraceptives
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what plans they have to include contraceptive care within the scope of their women's health strategy.
tabling member printed	Baroness Tonge
uin	HL10399
answer	answer is ministerial correction date of answer 24/11/2020 answer text <p>The All Party Parliamentary Group on Sexual and Reproductive Health’s report, <em>Women's Lives, Women's Rights: Strengthening Access to Contraception Beyond the COVID-19 Pandemic</em>, has raised a number of important issues. The recommendations including those relating to contraception care and data collection processes, will be considered as part of our upcoming work to develop the sexual and reproductive health strategy.</p> answering member printed Lord Bethell grouped question UIN HL10400 question first answered 24/11/2020 16:46:50 answering member 4708 label Biography information for Lord Bethell
tabling member	200 label Biography information for Baroness Tonge

1252026

registered interest
date	16/11/2020
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Contraceptives
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government, further to the report by the All-Party Parliamentary Group on Sexual and Reproductive Health Women's Lives, Women's Rights: Strengthening Access to Contraception Beyond the COVID-19 Pandemic, published on 10 September, what plans they have to include reviewing current data collection processes for (1) uptake, and (2) provision, of contraception in the national Sexual and Reproductive Health strategy.
tabling member printed	Baroness Tonge
uin	HL10400
answer	answer is ministerial correction date of answer 24/11/2020 answer text <p>The All Party Parliamentary Group on Sexual and Reproductive Health’s report, <em>Women's Lives, Women's Rights: Strengthening Access to Contraception Beyond the COVID-19 Pandemic</em>, has raised a number of important issues. The recommendations including those relating to contraception care and data collection processes, will be considered as part of our upcoming work to develop the sexual and reproductive health strategy.</p> answering member printed Lord Bethell grouped question UIN HL10399 question first answered 24/11/2020 16:46:50 answering member 4708 label Biography information for Lord Bethell
tabling member	200 label Biography information for Baroness Tonge

1246819

registered interest
date	27/10/2020
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Contraceptives
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government whether they recommend that a client has a consultation with a clinician prior to the purchase of emergency contraception.
tabling member printed	Baroness Tonge
uin	HL9685
answer	answer is ministerial correction date of answer 10/11/2020 answer text <p>It is a legal requirement that pharmacy (P) medicines, which include emergency hormonal contraception (EHC) products, can only be sold or supplied, or offered for sale or supply, from a registered pharmacy. The sale or supply must be undertaken by, or under the supervision of, a pharmacist. Information on the number of pharmacies in England that are unable to provide EHC in a confidential and a COVID-19 secure way is not collected centrally.</p><p>No assessment has been made centrally of the level of confidentiality in pharmacies for women who request EHC. However, most pharmacies now have a private consultation room where discussions with pharmacy staff can take place without being overheard. The Government has no specific plans to reclassify emergency contraceptive pills as a general sales list medication. Emergency contraceptive pills are currently available without prescription from pharmacies. Any applications to make them available on general sale from other retail outlets would be considered in accordance with the Government’s usual procedures by the Medicines and Healthcare products Regulatory Agency.</p> answering member printed Lord Bethell grouped question UIN HL9686 HL9687 HL9688 question first answered 10/11/2020 12:48:01 answering member 4708 label Biography information for Lord Bethell
tabling member	200 label Biography information for Baroness Tonge

1246820

registered interest
date	27/10/2020
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Contraceptives
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government how many pharmacies in England are unable to provide emergency contraception in (1) a confidential, and (2) a COVID-19 secure, way.
tabling member printed	Baroness Tonge
uin	HL9686
answer	answer is ministerial correction date of answer 10/11/2020 answer text <p>It is a legal requirement that pharmacy (P) medicines, which include emergency hormonal contraception (EHC) products, can only be sold or supplied, or offered for sale or supply, from a registered pharmacy. The sale or supply must be undertaken by, or under the supervision of, a pharmacist. Information on the number of pharmacies in England that are unable to provide EHC in a confidential and a COVID-19 secure way is not collected centrally.</p><p>No assessment has been made centrally of the level of confidentiality in pharmacies for women who request EHC. However, most pharmacies now have a private consultation room where discussions with pharmacy staff can take place without being overheard. The Government has no specific plans to reclassify emergency contraceptive pills as a general sales list medication. Emergency contraceptive pills are currently available without prescription from pharmacies. Any applications to make them available on general sale from other retail outlets would be considered in accordance with the Government’s usual procedures by the Medicines and Healthcare products Regulatory Agency.</p> answering member printed Lord Bethell grouped question UIN HL9685 HL9687 HL9688 question first answered 10/11/2020 12:48:01 answering member 4708 label Biography information for Lord Bethell
tabling member	200 label Biography information for Baroness Tonge

1246821

registered interest
date	27/10/2020
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Contraceptives
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what assessment they have made of the level of confidentiality in pharmacies for women who request emergency contraception.
tabling member printed	Baroness Tonge
uin	HL9687
answer	answer is ministerial correction date of answer 10/11/2020 answer text <p>It is a legal requirement that pharmacy (P) medicines, which include emergency hormonal contraception (EHC) products, can only be sold or supplied, or offered for sale or supply, from a registered pharmacy. The sale or supply must be undertaken by, or under the supervision of, a pharmacist. Information on the number of pharmacies in England that are unable to provide EHC in a confidential and a COVID-19 secure way is not collected centrally.</p><p>No assessment has been made centrally of the level of confidentiality in pharmacies for women who request EHC. However, most pharmacies now have a private consultation room where discussions with pharmacy staff can take place without being overheard. The Government has no specific plans to reclassify emergency contraceptive pills as a general sales list medication. Emergency contraceptive pills are currently available without prescription from pharmacies. Any applications to make them available on general sale from other retail outlets would be considered in accordance with the Government’s usual procedures by the Medicines and Healthcare products Regulatory Agency.</p> answering member printed Lord Bethell grouped question UIN HL9685 HL9686 HL9688 question first answered 10/11/2020 12:48:01 answering member 4708 label Biography information for Lord Bethell
tabling member	200 label Biography information for Baroness Tonge

1246822

registered interest
date	27/10/2020
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Contraceptives
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government, in the light of the COVID-19 pandemic, what plans they have to reclassify emergency hormonal contraception as a general sales list medication.
tabling member printed	Baroness Tonge
uin	HL9688
answer	answer is ministerial correction date of answer 10/11/2020 answer text <p>It is a legal requirement that pharmacy (P) medicines, which include emergency hormonal contraception (EHC) products, can only be sold or supplied, or offered for sale or supply, from a registered pharmacy. The sale or supply must be undertaken by, or under the supervision of, a pharmacist. Information on the number of pharmacies in England that are unable to provide EHC in a confidential and a COVID-19 secure way is not collected centrally.</p><p>No assessment has been made centrally of the level of confidentiality in pharmacies for women who request EHC. However, most pharmacies now have a private consultation room where discussions with pharmacy staff can take place without being overheard. The Government has no specific plans to reclassify emergency contraceptive pills as a general sales list medication. Emergency contraceptive pills are currently available without prescription from pharmacies. Any applications to make them available on general sale from other retail outlets would be considered in accordance with the Government’s usual procedures by the Medicines and Healthcare products Regulatory Agency.</p> answering member printed Lord Bethell grouped question UIN HL9685 HL9686 HL9687 question first answered 10/11/2020 12:48:01 answering member 4708 label Biography information for Lord Bethell
tabling member	200 label Biography information for Baroness Tonge

1236818

registered interest
date	22/09/2020
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Genito-urinary Medicine
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what self-care intervention sexual and reproductive health and rights services they support in the UK.
tabling member printed	Baroness Tonge
uin	HL8393
answer	answer is ministerial correction date of answer 07/10/2020 answer text <p>Local authorities in England are mandated to provide comprehensive open access sexual health services including sexually transmitted infection testing and treatment, notification of sexual partners of infected persons and access to the full range of contraception methods free from prescription charge. It is for local authorities to decide how these services are delivered.</p> answering member printed Lord Bethell question first answered 07/10/2020 13:46:09 answering member 4708 label Biography information for Lord Bethell
tabling member	200 label Biography information for Baroness Tonge